Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latin American Trade Agreements Loosen Pharmaceutical IP Rules

Executive Summary

The trade agreements the United States inked with Peru, Colombia and Panama set a new course for trade deals, easing restrictions that have made it more difficult for generic drugs to get on the market
Advertisement

Related Content

Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
Trans-Pacific Trade Agreement: GPhA, NGOs Oppose Proposed IP Provisions
Intellectual Property Bill Would Sanction Countries That Fail U.S. Rules
Intellectual Property Bill Would Sanction Countries That Fail U.S. Rules
U.S.-Israel Tussle Over IP Rights Continues; New Free Trade Policy Is Limited
U.S.-Israel Tussle Over IP Rights Continues; New Free Trade Policy Is Limited
Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Advertisement
UsernamePublicRestriction

Register

PS048522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel